Monday, August 20, 2012
It was not so long ago that
pharma as a sector was considered a dead zone by investors. All the mergers in
the world hadn't built value, while the pending patent cliff was a yawning
chasm that investors didn't want to get caught in.
What a difference a few years
makes. The other side of the patent cliff is in sight. With valuations severely
rebased, the potential for growth is becoming apparent in pipelines that have
been cleaned up to reflect the new realities of what payers want.